4.05
0.01 (0.25%)
| 前收盘价格 | 4.04 |
| 收盘价格 | 4.02 |
| 成交量 | 932,093 |
| 平均成交量 (3个月) | 2,424,656 |
| 市值 | 223,808,272 |
| 预期市盈率 (P/E Forward) | 8.98 |
| 价格/销量 (P/S) | 3.91 |
| 52周波幅 | |
| 利润日期 | 8 May 2025 - 12 May 2025 |
| 营业利益率 (TTM) | -79,817.02% |
| 稀释每股收益 (EPS TTM) | -1.42 |
| 季度收入增长率 (YOY) | 32.30% |
| 流动比率 (MRQ) | 0.290 |
| 营业现金流 (OCF TTM) | -30.76 M |
| 杠杆自由现金流 (LFCF TTM) | -22.81 M |
| 资产报酬率 (ROA TTM) | -633.94% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Checkpoint Therapeutics, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 1.0 |
| 内部交易活动 | NA |
| 价格波动 | -4.5 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | 4.0 |
| 平均 | -0.50 |
|
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 19.83% |
| 机构持股比例 | 33.01% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Wealth Enhancement Advisory Services, Llc | 31 Dec 2024 | 425,000 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 4.80 (D. Boral Capital, 18.52%) | 购买 |
| 中 | 4.10 (1.24%) | |
| 低 | 4.10 (Lake Street, 1.24%) | 保留 |
| 4.10 (HC Wainwright & Co., 1.24%) | 保留 | |
| 平均值 | 4.33 (6.91%) | |
| 总计 | 1 购买, 2 保留 | |
| 平均价格@调整类型 | 4.01 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| D. Boral Capital | 31 Mar 2025 | 4.80 (18.52%) | 购买 | 4.04 |
| 10 Mar 2025 | 4.80 (18.52%) | 购买 | 3.98 | |
| HC Wainwright & Co. | 11 Mar 2025 | 4.10 (1.23%) | 保留 | 4.00 |
| Lake Street | 10 Mar 2025 | 4.10 (1.23%) | 保留 | 3.98 |
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 28 Mar 2025 | 公告 | Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates |
| 09 Mar 2025 | 公告 | Sun Pharma to Acquire Checkpoint Therapeutics |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合